Volume 22, Number 9—September 2016
Dispatch
Multidrug-Resistant Shigella Infections in Patients with Diarrhea, Cambodia, 2014–2015
Table 2
Isolate no. | Organism | Antimicrobial resistance | CIP MIC, µg/mL† | Amino acid substitutions in QRDR |
AZM MIC, µg/mL‡ | mphA gene | ESBL confirmatory test | β-lactamase genes | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
gyrA |
parC |
|||||||||||
Ser 83 | Asp 87 | Ser 57 | Ser 80 | |||||||||
1 | S. flexneri 2a | AMP-SXT-TET-NAL | 0.25 | Leu | – | – | – | 2.00 | Neg | Neg | TEM-1, OXA-1 | |
2 | S. flexneri 2a | AMP-SXT-TET-NAL | 0.25 | Leu | – | – | – | 1.50 | Neg | Neg | TEM-1, OXA-1 | |
3 | S. flexneri 2v | AMP-SXT-TET-NAL | 0.19 | Leu | – | – | – | 1.50 | Neg | Neg | TEM-1, OXA-1 | |
4 | S. flexneri 3a | AMP-SXT-TET-NAL | 0.25 | Leu | – | – | – | 1.00 | Neg | Neg | TEM-1 | |
5 | S. flexneri 3a | AMP-SXT-TET-NAL | 0.19 | Leu | – | – | – | 1.50 | Neg | Neg | TEM-1 | |
6 | S. flexneri 3a | AMP-SXT-TET-NAL-CIP | 4.00 | Leu | – | Arg | – | 0.75 | Neg | Neg | TEM-1 | |
7 | S. flexneri 3a | AMP-SXT-TET-NAL-CIP | 4.00 | Leu | – | Arg | – | 1.00 | Neg | Neg | TEM-1 | |
8 | S. flexneri 3a | AMP-SXT-TET-NAL-CIP | 4.00 | Leu | – | Arg | – | 1.00 | Neg | Neg | TEM-1 | |
9 | S. flexneri 3a | AMP-SXT-TET-NAL-CIP-AZM-CRO-CTX | 6.00 | Leu | – | Arg | – | 32.00 | Pos | Pos | TEM-1, CTX-M-27 | |
10 | S. sonnei | AMP-SXT-TET-NAL-CIP-CRO-CTX-CAZ | 6.00 | Leu | Gly | – | Ile | 4.00 | Neg | Pos | CTX-M-55 |
*AMP, ampicillin; Arg, arginine; Asp, aspartate; AZM, azithromycin; CAZ, ceftazidime; CIP; ciprofloxacin; CRO, ceftriaxone; CTX, cefotaxime; ESBL, extended-spectrum β-lactamase; Gly, glycine; Ile, isoleucine; Leu, leucine; NAL, nalidixic acid; Neg, negative; Pos, positive; QRDR, quinolone-resistance determining region; Ser, serine; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; –, no amino acid substitutions found.
†CIP MIC interpretive criteria for Enterobacteriaceae is susceptible <1, resistant >4 µg/mL.
‡AZM MIC interpretive criteria for Salmonella enterica serovar Typhi is susceptible <16, resistant >32 µg/mL.
Page created: August 16, 2016
Page updated: August 16, 2016
Page reviewed: August 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.